In a bold move, President Trump is set to sign an executive order mandating the U.S. health department to negotiate lower drug prices with pharmaceutical companies. This could drastically change healthcare costs for millions of Americans.
In a groundbreaking move, President Trump has issued an executive order aimed at ending the price discrimination faced by American consumers in the pharmaceutical market. This order seeks to ensure that Americans pay the same low prices for medications as those in other developed nations, addressing the long-standing issue of subsidizing global pharmaceutical profits.
President Trump unveils a groundbreaking executive order aimed at slashing U.S. drug prices by matching them to those in developed countries. Will this initiative reshape the pharmaceutical landscape and benefit American patients?
In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
President Trump is set to sign an executive order aiming to lower drug prices in the US by aligning them with prices in wealthy nations. This 'most favored nation' model could face legal challenges.
In a surprising announcement, Trump declares he will sign an executive order to slash prescription drug prices in the U.S. to match those of other high-income countries, potentially reducing costs by 30% to 80%.
Casey Means, a controversial figure in the health sector, faces backlash from MAGA influencers and former allies as she advocates for lifestyle changes to prevent chronic diseases. Discover the tensions surrounding her nomination and her views on vaccines.
In a surprising move, President Trump has nominated Casey Means, a health entrepreneur and advocate for a controversial health agenda, as the new Surgeon General, replacing Janette Nesheiwat amid credential controversies.
In a pivotal court ruling, Judge Mark Pittman denied compounding pharmacies' request for an injunction against the FDA's decision on the semaglutide shortage. This ruling keeps strict timelines for exiting the market, leaving many in the industry concerned.
